- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04529707
Sleep Intervention in Young Boys with Duchenne Muscular Dystrophy (DMD)
Sleep Health Dysfunction and the Use of a Transdiagnostic Sleep Intervention in Duchenne Muscular Dystrophy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pre-phase (2 weeks in duration):
Initial Interview: Following informed consent and enrollment, participants will complete a 45-60 minute interview with research investigators using video web conferencing (e.g., Zoom). If the participant agrees, this interview will be recorded. During this interview, investigators will gather descriptive data to characterize the sample including information regarding: 1) the child (age, disease severity for DMD, weight/ height, race/ethnicity, location (rural/suburban/urban), grade in school, medication use); 2) the parent (race/ethnicity, marital status, work status, education level, income); 3) the child's sleep environment (technology/telephone access, darkness, temperature, bed/bedroom sharing); 4) the child's daily activities and routines (current wake-up time & routines; activities in the home; activities at school and after school); and 5) the child's nighttime routines (activities prior to bedtime; current bedtime routine; technology use prior to bedtime).
ActiGraph: Each parent-child dyad will be mailed a package containing the Actigraph GT9x with wristband, charging device, a manual of operating procedures (MOP) providing all technical and protocol instructions, and phone numbers for research team support. Throughout the 2-week pre-phase data collection period, parents will be required to log and push data from their child's Actigraph to a secure cloud service, CentrePoint, via Wi-Fi each day. This will be accomplished through an app and all data will be de-identified.
Intervention Implementation Phase (10-week duration):
Training Modules: During the intervention phase, weekly video-conference meetings will be held where trained clinicians will guide parents through approximately 60-minute web-based modules using a video-conferencing platform (e.g., Zoom). These sessions will focus on education, dynamic parent training (child-related goal-setting and problem-solving), assessment of sleep health dimensions, and development of a weekly sleep and activity diary. Parents will be provided with a personalized TranS-CY Parent Workbook, which contains information regarding each of the 10 weekly modules. Each weekly session will be agenda driven with the option to revise the agenda based on family needs. Children/youth with DMD will be invited to attend the sessions and provide as much feedback as possible. Data will be collected on parent attendance to assess intervention adoption. Each week, clinicians will request feedback on the previous week's session and provide additional educational support for the previous content should it be required.
Intervention Questionnaires: During the 10-week intervention phase, parents will be asked to complete knowledge checks every 2-3 weeks in order to confirm understanding of the module information (primary outcome). These questionnaires will either be asked verbally during the session or questions will be sent to the parent's email through Qualtrics, a HIPAA compliant survey software platform. Hard copies of the knowledge checks will be sent if the parent prefers.
Sleep and Activity Log: Throughout the intervention phase, parents will be asked to complete a daily sleep and activity log covering their child's day. This log will be sent to their emails using Qualtrics. Each log will take approximately 3-5 minutes to complete.
Post-Intervention Phase (2 weeks):
ActiGraph: At the end of the 10-week intervention, each participant (parent-child dyad) will again be mailed an Actigraph GT9x, all accessories and protocols. Throughout the 2-week post-phase data collection period, parents will again use their personal smart-phone app to log and push data from the Actigraph to CentrePoint, via Wi-Fi each day. Data from the Actigraph GT9x will be provide the secondary outcome of percent sleep efficiency. Investigators will explore change in percent sleep efficiency at pre-post 10 week TranS-CY intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15219
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Parents/caregivers of youth between ages 6 and 17 with a primary diagnosis of Duchenne muscular dystrophy (DMD) who lives at home .
- Access to a smart-phone or computer and internet for the weekly web-based sessions, as well as uploading of the Actigraph data;
- English speaking.
Exclusion Criteria:
- Unable to speak or read English
- Their child with DMD has cognitive or behavioral concerns that would limit participation and follow-through of intervention;
- Their child/youth with DMD is currently receiving an intervention for a sleep related disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Sleep Intervention
All participants will engage in a 10-week, parent mediated sleep intervention with weekly education sessions.
|
The Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-CY) uses a comprehensive sleep health framework along with robust evidence for promoting healthy sleep patterns in youth.
The TranS-CY incorporates best practices from numerous efficacious behavioral sleep interventions including 1) cognitive behavioral therapy, 2) interpersonal and social rhythm therapy, and 3) behavioral treatment of circadian rhythm sleep-wake disorders.
The "traditional" TranS-CY is clinician-led and provides a robust sleep treatment framework for youth with a wide range of disorders and sleep health concerns.
For this study, investigators are using the basic framework of the TranS-CY, but clinicians will train parents to incorporate the intervention into the home for their young child with DMD.
Trained clinicians will work with parents to ensure the basic components of the TranS-CY are incorporated into the home-based intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Parent Mastery Questionnaire
Time Frame: A 10-item questionnaire focused on intervention modules will be delivered every 2-3 weeks during the 10 week intervention. Parents will be required to answer questions that address their knowledge of the information provided in each module.
|
100% of parents who are retained throughout the study will attain ≥80% knowledge accuracy at each knowledge check time point and will accurately answer 8 of the 10 questions provided.
|
A 10-item questionnaire focused on intervention modules will be delivered every 2-3 weeks during the 10 week intervention. Parents will be required to answer questions that address their knowledge of the information provided in each module.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Child intradaily variability from Actigraphy
Time Frame: 2 weeks pre-intervention and 2 weeks post-intervention
|
Vector magnitude scores from Actigraphy for each 2-week data collection period (pre and post intervention) are analyzed through nParAct software.
Analyses provide us with our secondary outcome of intradaily variability.
Intradaily variability is the frequency and extent of transitions between periods of rest and activity on an hourly basis over 24 hours.
Relative amplitude is how active a child is during a 24 hour period.
|
2 weeks pre-intervention and 2 weeks post-intervention
|
|
Child relative amplitude from Actigraph
Time Frame: 2 weeks pre-intervention and 2 weeks post-intervention.
|
Vector magnitude scores from Actigraphy for each 2-week data collection period (pre and post intervention) are analyzed through nParAct software.
Analyses provide us with our secondary outcome of relative amplitude.
Relative amplitude is how active a child is during a 24 hour period.
|
2 weeks pre-intervention and 2 weeks post-intervention.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Angela Caldwell, PhD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY20030019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Dyne TherapeuticsRecruitingMuscular Dystrophies | Muscular Dystrophy, Duchenne | Duchenne Muscular Dystrophy (DMD) | Muscular Dystrophy, Duchenne and Becker Types | Genetic Disease, X-Linked | Genetic Disease, Inborn | DMD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Muscular Dystrophy (DMD) | Muscular Dystrophies... and other conditionsUnited States
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Universitaire Ziekenhuizen KU LeuvenRecruitingDuchenne Muscular Dystrophy (DMD)Belgium
-
Peking Union Medical College HospitalActive, not recruitingDuchenne Muscular Dystrophy (DMD)China
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
-
Ondokuz Mayıs UniversityCompletedDuchenne Muscular Dystrophy (DMD)Turkey
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Parent Project, ItalyCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
GenethonInstitute of MyologyCompletedDuchenne Muscular Dystrophy (DMD)France
Clinical Trials on Transdiagnostic Behavioral Sleep Intervention
-
Chinese University of Hong KongNot yet recruiting
-
University of California, BerkeleyCompletedImplementing and Sustaining a Sleep Treatment to Improve Community Mental Health Part 3: SustainmentSleep Wake Disorders | Circadian Rhythm DisordersUnited States
-
University of California, BerkeleyUniversity of Pittsburgh; Alameda County Behavioral Health Care ServicesCompletedMental DisordersUnited States
-
University of California, BerkeleyCompletedSleep Disorder | Memory ImpairmentUnited States
-
Chinese University of Hong KongNot yet recruitingDepression | Sleep Disorders, Circadian RhythmHong Kong
-
Chinese University of Hong KongUniversity of California, BerkeleyUnknownSleep Disturbance | Major Depressive DisorderHong Kong
-
Chinese University of Hong KongUniversity of California, BerkeleyCompleted
-
Children's Hospital Medical Center, CincinnatiCompleted
-
University of California, BerkeleyCompletedSleep Disorder | Feasibility | Sleep Disorders, Circadian Rhythm | Adaptation | Acceptability | Implementation ResearchUnited States
-
University of California, BerkeleyCompletedSleep Disorder | Circadian DysregulationUnited States